IDH1 and infantile convulsions and choreoathetosis: More recently, molecularly targeted therapies including, but not limited to, the inhibitors of the isocitrate dehydrogenase 1 (IDH1) and fibroblast growth factor receptor (FGFR) have proven effective in a molecularly selected subgroup of patients with iCCA after at least one previous line of systemic treatment and have received approval by international regulatory agencies for use in this setting [8,9,10,11].